Fertility: There are no data in humans to evaluate the effect of topical corticosteroids on fertility.
Clobetasol administered subcutaneously to rats had no effect upon mating performance; however, fertility was decreased at the highest dose (see Non-clinical Information).
Pregnancy: There are limited data from the use of Clobetasol propionate (Dermovate) in pregnant women.
Topical administration of corticosteroids to pregnant animals can cause abnormalities of foetal development (see Pharmacology: Toxicology: Preclinical Safety Data under Actions).
The relevance of this finding to humans has not been established. Administration of Clobetasol propionate (Dermovate) during pregnancy should only be considered if the expected benefit to the mother outweighs the risk to the foetus. The minimum quantity should be used for the minimum duration.
Lactation: The safe use of topical corticosteroids during lactation has not been established.
It is not known whether the topical administration of corticosteroids could result in sufficient systemic absorption to produce detectable amounts in breast milk. Administration of Clobetasol propionate (Dermovate) during lactation should only be considered if the expected benefit to the mother outweighs the risk to the infant.